Who is sponsoring NCT02547233?

NCT02547233 is sponsored by LEO Pharma.

What condition does NCT02547233 study?

NCT02547233 studies Actinic Keratosis.

What drugs are being tested in NCT02547233?

Interventions: LEO 43204 gel, Vehicle gel.

What is the status of NCT02547233?

NCT02547233 is currently COMPLETED.

Last reviewed 2025-02-21 · How we verify

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

NCT02547233 Phase 3 COMPLETED Results posted

The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment.

Details

Lead sponsor	LEO Pharma
Phase	Phase 3
Status	COMPLETED
Enrolment	437
Start date	2015-11
Completion	2017-11

Conditions

Actinic Keratosis

Interventions

LEO 43204 gel
Vehicle gel

Primary outcomes

Percentage of Participants With Complete Clearance of Actinic Keratosis (AK) — At Week 8
Complete clearance was defined as an AK count of zero, i.e. no clinically visible AKs (actinic keratosis lesions) in the treatment area. The table shows the percentage of mean number of subjects across imputations with complete clearance.

Countries

United States